Agendia’s MammaPrint® Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
– HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS — Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint®’s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van ‘t Veer, from the Netherlands Cancer Institute, presented…